News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,354 Results
Type
Article (14459)
Company Profile (117)
Press Release (264778)
Section
Business (91652)
Career Advice (489)
Deals (16091)
Drug Delivery (65)
Drug Development (38899)
Employer Resources (53)
FDA (6758)
Job Trends (6692)
News (157361)
Policy (14557)
Tag
Academia (553)
Alliances (24334)
Alzheimer's disease (413)
Approvals (6769)
Artificial intelligence (77)
Bankruptcy (147)
Best Places to Work (4850)
Biotechnology (49)
Breast cancer (69)
Cancer (511)
Cardiovascular disease (50)
Career advice (428)
Cell therapy (85)
Clinical research (32428)
Collaboration (254)
Compensation (97)
COVID-19 (824)
C-suite (81)
Data (548)
Diabetes (66)
Diagnostics (1432)
Drug pricing (59)
Earnings (32899)
Events (39708)
Executive appointments (281)
FDA (7060)
Funding (173)
Gene therapy (80)
GLP-1 (320)
Government (1356)
Healthcare (4374)
Infectious disease (851)
Inflammatory bowel disease (56)
Interviews (63)
IPO (6204)
Job creations (2083)
Job search strategy (393)
Layoffs (176)
Legal (3476)
Lung cancer (82)
Manufacturing (115)
Medical device (1686)
Medtech (1688)
Mergers & acquisitions (10002)
Metabolic disorders (205)
Neuroscience (550)
NextGen: Class of 2025 (1785)
Non-profit (773)
Northern California (601)
Obesity (122)
Opinion (115)
Patents (74)
People (29599)
Pharmaceutical (69)
Phase I (8569)
Phase II (13817)
Phase III (12186)
Pipeline (252)
Policy (49)
Postmarket research (1425)
Preclinical (3537)
Radiopharmaceuticals (123)
Rare diseases (133)
Real estate (2735)
Regulatory (10378)
Research institute (655)
Resumes & cover letters (57)
Southern California (578)
Startups (1716)
United States (6037)
Vaccines (133)
Weight loss (88)
Date
Today (67)
Last 7 days (191)
Last 30 days (813)
Last 365 days (13598)
2025 (773)
2024 (13762)
2023 (15533)
2022 (21201)
2021 (21738)
2020 (20715)
2019 (16570)
2018 (12738)
2017 (14706)
2016 (13929)
2015 (16358)
2014 (13029)
2013 (11116)
2012 (11859)
2011 (12381)
2010 (11255)
Location
Africa (330)
Arizona (49)
Asia (20713)
Australia (2693)
California (1409)
Canada (750)
China (178)
Colorado (55)
Connecticut (58)
Europe (40793)
Florida (273)
Illinois (167)
Indiana (106)
Japan (59)
Kansas (53)
Maryland (212)
Massachusetts (1204)
Minnesota (74)
New Jersey (614)
New York (477)
North Carolina (331)
Northern California (601)
Pennsylvania (366)
South America (528)
Southern California (578)
Texas (219)
Virginia (50)
Washington State (108)
279,354 Results for "spectrum pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Piccolo Medical, Inc. Announces Distribution Agreement with Spectrum Vascular
January 13, 2025
·
2 min read
Press Releases
Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals
October 8, 2024
·
7 min read
Pharm Country
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.
May 6, 2024
·
8 min read
Pharm Country
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family, with both inhalation and skin abrasion modes of infection acquisition.
May 8, 2024
·
8 min read
Drug Development
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, announced that it has completed enrollment in its Phase 1 trial with OVX033, the company’s broad-spectrum vaccine candidate against sarbecoviruses.
June 25, 2024
·
3 min read
Press Releases
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
January 14, 2025
·
4 min read
Pharm Country
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals was achieved.
May 14, 2024
·
7 min read
Pharm Country
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.
June 24, 2024
·
8 min read
Pharm Country
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, Inc., a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its development of a first-in-class, broad-spectrum antiviral agent that could revolutionize treatment of viral infections including RSV, COVID, Influenzas and other viruses.
May 29, 2024
·
9 min read
Drug Development
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
STALICLA SA announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder, named ASD Phenotype 1.
June 27, 2024
·
3 min read
1 of 27,936
Next
